302 related articles for article (PubMed ID: 28115333)
1. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
3. Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Russo A; Falcone M; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale PL; Oliver A; Ruiz-Garbajosa P; Gasch O; Gozalo M; Pitout J; Akova M; Peña C; Cisneros JM; Hernández-Torres A; Farcomeni A; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Karaiskos I; de la Calle C; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Rodriguez-Gomez J; Souli M; Bonomo RA; Paterson DL; Carmeli Y; Pascual A; Rodríguez-Baño J; Venditti M;
Int J Antimicrob Agents; 2018 Nov; 52(5):577-585. PubMed ID: 29969692
[TBL] [Abstract][Full Text] [Related]
4. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project).
Pierrotti LC; Pérez-Nadales E; Fernández-Ruiz M; Gutiérrez-Gutiérrez B; Tan BH; Carratalà J; Oriol I; Paul M; Cohen-Sinai N; López-Medrano F; San-Juan R; Montejo M; Freire MP; Cordero E; David MD; Merino E; Mehta Steinke S; Grossi PA; Cano Á; Seminari EM; Valerio M; Gunseren F; Rana M; Mularoni A; Martín-Dávila P; van Delden C; Hamiyet Demirkaya M; Koçak Tufan Z; Loeches B; Iyer RN; Soldani F; Eriksson BM; Pilmis B; Rizzi M; Coussement J; Clemente WT; Roilides E; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Aguado JM;
Transpl Infect Dis; 2021 Jun; 23(3):e13520. PubMed ID: 33222379
[TBL] [Abstract][Full Text] [Related]
6. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study.
Giannella M; Pascale R; Ferraro G; Toschi A; Pancaldi L; Furii F; Bartoletti M; Tedeschi S; Ambretti S; Lewis RE; Viale P
Int J Antimicrob Agents; 2019 May; 53(5):574-581. PubMed ID: 30639527
[TBL] [Abstract][Full Text] [Related]
8. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
9. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA; Pezzani MD; Gutiérrez-Gutiérrez B; Viale P; Hsueh PR; Ruiz-Garbajosa P; Venditti M; Tumbarello M; Navarro-Francisco C; Calbo E; Akova M; Giamarellou H; Oliver A; Almirante B; Gasch O; Martínez-Martínez L; Schwaber MJ; Daikos G; Pitout J; Peña C; Hernández-Torres A; Doi Y; Pérez F; Tuon FF; Tacconelli E; Carmeli Y; Bonomo RA; Pascual Á; Paterson DL; Rodríguez-Baño J;
Int J Antimicrob Agents; 2017 Nov; 50(5):664-672. PubMed ID: 28782704
[TBL] [Abstract][Full Text] [Related]
10. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates.
Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244
[TBL] [Abstract][Full Text] [Related]
11. Comparison of empirical therapy with cefoperazone/sulbactam or a carbapenem for bloodstream infections due to ESBL-producing Enterobacteriaceae.
Su J; Guo Q; Li Y; Wu S; Hu F; Xu S; Wang M
J Antimicrob Chemother; 2018 Nov; 73(11):3176-3180. PubMed ID: 30099554
[TBL] [Abstract][Full Text] [Related]
12. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
13. Comparison of therapy with β-lactam/β-lactamase inhibitor combinations or carbapenems for bacteraemia of nonurinary source caused by ESBL-producing Escherichia coli or Klebsiella pneumoniae.
Luo H; Xiao Y; Hang Y; Chen Y; Zhu H; Fang X; Cao X; Zou S; Hu X; Xiong J; Zhong Q; Hu L
Ann Clin Microbiol Antimicrob; 2021 Sep; 20(1):63. PubMed ID: 34488786
[TBL] [Abstract][Full Text] [Related]
14. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
Zhang H; Liang B; Wang J; Cai Y
Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
[TBL] [Abstract][Full Text] [Related]
15. Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?
Bassetti M; Giacobbe DR; Robba C; Pelosi P; Vena A
Curr Opin Infect Dis; 2020 Dec; 33(6):474-481. PubMed ID: 33060469
[TBL] [Abstract][Full Text] [Related]
16. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Harris PN; Tambyah PA; Paterson DL
Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
[TBL] [Abstract][Full Text] [Related]
17. Editorial commentary: Bloodstream infection caused by extended-spectrum β-lactamase-producing Gram-negative bacteria: how to define the best treatment regimen?
Perez F; Bonomo RA
Clin Infect Dis; 2015 May; 60(9):1326-9. PubMed ID: 25586684
[No Abstract] [Full Text] [Related]
18. Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
López-Cortés LE; Rosso-Fernández C; Núñez-Núñez M; Lavín-Alconero L; Bravo-Ferrer J; Barriga Á; Delgado M; Lupión C; Retamar P; Rodríguez-Baño J;
BMJ Open; 2017 Jun; 7(6):e015439. PubMed ID: 28601833
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
